Predictive biomarkers and the role of the microbiome determining response to antiinflammatory treatment in Inflammatory Bowel Disease (Crohn's disease and ulcerative colitis)

Predictive biomarkers and the role of the microbiome determining response to antiinflammatory treatment in Inflammatory Bowel Disease (Crohn's disease and ulcerative colitis) - Predictive biomarkers and the role of microbiome on treatment for IBD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50413

Enrollment

2240

Registered

2015-10-30

Start date

2015-11-03

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease inflammatory Bowel Disease ulcerative colitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Crohn's disease ulcerative colitis Inflammatory Bowel disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Determination of concentrations of cytokines and chemokines, presence of inflammatory cell subtypes and identification of mucosal microbiome in biopsies taken from patients with active IBD before/during/after the start of new anti-inflammatory treatment.	—

Secondary

Measure	Time frame
Determination of patients: - Genotype (including whole genome methylome and transcriptome) - Luminal microbiome - Serum cytokines and chemokines is associated with mucosal immunotype and microbiome in relationship to treatment response	—

Countries

Netherlands

Outcome results